Histological findings of thyroid cancer after lenvatinib therapy.
Okubo Y, Toda S, Sato S, Yoshioka E, Ono K, Hasegawa C, Washimi K, Yokose T, Miyagi Y, Iwasaki H, Hayashi H.
Okubo Y, et al.
Histopathology. 2023 Oct;83(4):657-663. doi: 10.1111/his.15013. Epub 2023 Jul 28.
Histopathology. 2023.
PMID: 37501641
AIMS: Lenvatinib is a multikinase inhibitor used for treating unresectable or metastatic cancers, including thyroid cancer. As total thyroidectomy followed by radioactive iodine therapy is a commonly recommended initial treatment for thyroid cancer, histologi …
AIMS: Lenvatinib is a multikinase inhibitor used for treating unresectable or metastatic cancers, including thyroid cancer. As …